脂蛋白相关磷脂酶A2与冠心病的关系及不同剂量阿托伐他汀的治疗作用
|
摘要
研究背景
研究显示,冠状动脉粥样硬化性疾病是一种慢性炎症性疾病,炎症因子在动脉粥样硬化发生发展过程中起着重要的作用,而抗炎治疗也成为动脉硬化防治的新领域。脂蛋白相关磷脂酶A2(Lp-PLA2)是一种炎症因子,研究表明,在动脉粥样硬化斑块中Lp-PLA2升高,且与斑块的不稳定性相关,是冠心病的独立危险因素。他汀类药物具有抗炎等降脂外的作用,对稳定斑块,改善冠心病的预后起着重要的作用。
目的
探讨脂蛋白相关磷脂酶A2与冠状动脉粥样硬化病变程度及斑块稳定性的关系；应用不同剂量的阿托伐他汀对冠心病患者血清Lp-PLA2的影响。
方法
对86例可疑冠心病患者行冠脉造影,根据冠脉造影结果分为对照组(24例)和冠心病组(62例),冠心病组随机分为2组,分别给予阿托伐他汀20mg及80mg。根据临床类型分为急性冠脉综合征组(42例)和稳定型心绞痛组(20例)。以病变支数和Gensini积分评价动脉粥样硬化病变程度,以临床分型评价斑块稳定性。检查所有患者入院时血清Lp-PLA2水平、hs-CRP等指标,分析Lp-PLA2、hs-CRP等与冠状动脉病变支数、Gensini积分、斑块稳定性的关系。1周后再次抽血测定其Lp-PLA2值、hs-CRP等,比较口服不同剂量阿托伐他汀对Lp-PLA2值、hs-CRP的影响。
结果
冠心病组Lp-PLA2活性显著高于对照组(P<0.05),而且随着冠脉病变支数的增加和Gensini积分的增加而逐渐升高。在急性冠脉综合征组较稳定型心绞痛组升高。Lp-PLA2活性与hs-CRP无明显相关性。口服阿托伐他汀1周后Lp-PLA2值、hs-CRP均下降,大剂量80mg组较常规剂量20mg组血清Lp-PLA2、hs-CRP水平下降更明显。
结论
冠心病患者血清Lp-PLA2水平与冠状动脉粥样硬化病变程度及斑块稳定性有关。口服大剂量阿托伐他汀1周后较常规剂量组更能降低血清Lp-PLA2、hs-CRP水平。
Background
It is indicated that coronary atherosclerosis disease (CHD) is a disease of chronic inflammation, inflammation plays an important role in the development and progress of atherosclerosis, and anti-inflammatory therapy comes a frontier of atherosclerosis prevention. Lipoprotein-associated pospholipase A2 (Lp-PLA2) is a inflammation factor, lots of studies showed that Lp-PLA2 increased in the atherosclerotic plaque, and is correlated to the stability. It is a independent risk factor of CHD. Statins has anti-inflammatory effect except for reduce blood fat. It also can stable plaque and improve prognosis of CHD.
Objective
To investigate the correlations between serum levels of lipoprotein-associated pospholipase A2 and the severity and stability of coronary atherosclerosis. To observe the influence of different dosage of atorvastatin play on plasma Lp-PLA2 of coronary artery disease patients.
Methods
Coronary angiography (CAG) was performed in 86 patients who were suspected as having coronary artery disease(CHD). According to the coronary artery chanrges and plaque characters in CAG, all patients were divided into control group(n=24) and CHD group(n=62). According to the clinical types, the CHD patients were divided into acute coronary syndrome (ACS) group (n=42) and stable angina pectoris (SAP) group (n=20). According to the dose of atorvastatin, CHD group was divide into two groups in random, and was given 20mg and 80mg atorvastatin every night. The number of diseased coronary branches and Gensini's score is use for evaluate the severity of atherosclerosis. The clinical types is use for evaluate the stability of plaque. Lp-PLA2 and hs-CRP were measured in all the patients. The correlation between serum Lp-PLA2 with hs-CRP and the number of diseased coronary branches, Gensini's score, clinical types were analyzed. The CHD group were withdrawal one week later, determine the serum Lp-PLA2 level and hs-CRP. Compare the influence of different dosage of atorvastain.
Results
Lp-PLA2 in CHD patients was significantly higher than that in control group(P<0.05) and increased with the increasing number of diseased coronary branches and Gensini's score. Lp-PLA2 in ACS group was higher than SAP group. Lp-PLA2 level had no correlated with hs-CRP. Lp-PLA2 level was lower in the patients were given 80mg atorvastatin than 20mg.
Conclusion
CHD patients serum Lp-PLA2 level is correlated with the severity of atherosclerosis and the stability of plaque. Take atorvastatins 80mg/d for one week could depress Lp-PLA2 and hs-CRP more than routine dose.
研究显示,冠状动脉粥样硬化性疾病是一种慢性炎症性疾病,炎症因子在动脉粥样硬化发生发展过程中起着重要的作用,而抗炎治疗也成为动脉硬化防治的新领域。脂蛋白相关磷脂酶A2(Lp-PLA2)是一种炎症因子,研究表明,在动脉粥样硬化斑块中Lp-PLA2升高,且与斑块的不稳定性相关,是冠心病的独立危险因素。他汀类药物具有抗炎等降脂外的作用,对稳定斑块,改善冠心病的预后起着重要的作用。
目的
探讨脂蛋白相关磷脂酶A2与冠状动脉粥样硬化病变程度及斑块稳定性的关系；应用不同剂量的阿托伐他汀对冠心病患者血清Lp-PLA2的影响。
方法
对86例可疑冠心病患者行冠脉造影,根据冠脉造影结果分为对照组(24例)和冠心病组(62例),冠心病组随机分为2组,分别给予阿托伐他汀20mg及80mg。根据临床类型分为急性冠脉综合征组(42例)和稳定型心绞痛组(20例)。以病变支数和Gensini积分评价动脉粥样硬化病变程度,以临床分型评价斑块稳定性。检查所有患者入院时血清Lp-PLA2水平、hs-CRP等指标,分析Lp-PLA2、hs-CRP等与冠状动脉病变支数、Gensini积分、斑块稳定性的关系。1周后再次抽血测定其Lp-PLA2值、hs-CRP等,比较口服不同剂量阿托伐他汀对Lp-PLA2值、hs-CRP的影响。
结果
冠心病组Lp-PLA2活性显著高于对照组(P<0.05),而且随着冠脉病变支数的增加和Gensini积分的增加而逐渐升高。在急性冠脉综合征组较稳定型心绞痛组升高。Lp-PLA2活性与hs-CRP无明显相关性。口服阿托伐他汀1周后Lp-PLA2值、hs-CRP均下降,大剂量80mg组较常规剂量20mg组血清Lp-PLA2、hs-CRP水平下降更明显。
结论
冠心病患者血清Lp-PLA2水平与冠状动脉粥样硬化病变程度及斑块稳定性有关。口服大剂量阿托伐他汀1周后较常规剂量组更能降低血清Lp-PLA2、hs-CRP水平。
Background
It is indicated that coronary atherosclerosis disease (CHD) is a disease of chronic inflammation, inflammation plays an important role in the development and progress of atherosclerosis, and anti-inflammatory therapy comes a frontier of atherosclerosis prevention. Lipoprotein-associated pospholipase A2 (Lp-PLA2) is a inflammation factor, lots of studies showed that Lp-PLA2 increased in the atherosclerotic plaque, and is correlated to the stability. It is a independent risk factor of CHD. Statins has anti-inflammatory effect except for reduce blood fat. It also can stable plaque and improve prognosis of CHD.
Objective
To investigate the correlations between serum levels of lipoprotein-associated pospholipase A2 and the severity and stability of coronary atherosclerosis. To observe the influence of different dosage of atorvastatin play on plasma Lp-PLA2 of coronary artery disease patients.
Methods
Coronary angiography (CAG) was performed in 86 patients who were suspected as having coronary artery disease(CHD). According to the coronary artery chanrges and plaque characters in CAG, all patients were divided into control group(n=24) and CHD group(n=62). According to the clinical types, the CHD patients were divided into acute coronary syndrome (ACS) group (n=42) and stable angina pectoris (SAP) group (n=20). According to the dose of atorvastatin, CHD group was divide into two groups in random, and was given 20mg and 80mg atorvastatin every night. The number of diseased coronary branches and Gensini's score is use for evaluate the severity of atherosclerosis. The clinical types is use for evaluate the stability of plaque. Lp-PLA2 and hs-CRP were measured in all the patients. The correlation between serum Lp-PLA2 with hs-CRP and the number of diseased coronary branches, Gensini's score, clinical types were analyzed. The CHD group were withdrawal one week later, determine the serum Lp-PLA2 level and hs-CRP. Compare the influence of different dosage of atorvastain.
Results
Lp-PLA2 in CHD patients was significantly higher than that in control group(P<0.05) and increased with the increasing number of diseased coronary branches and Gensini's score. Lp-PLA2 in ACS group was higher than SAP group. Lp-PLA2 level had no correlated with hs-CRP. Lp-PLA2 level was lower in the patients were given 80mg atorvastatin than 20mg.
Conclusion
CHD patients serum Lp-PLA2 level is correlated with the severity of atherosclerosis and the stability of plaque. Take atorvastatins 80mg/d for one week could depress Lp-PLA2 and hs-CRP more than routine dose.
引文
[1]Ross R. Atherosclerosis-an inflammatory disease. N Engl J. Med,1999,340:115-126.
[2]Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies:Part Ⅰ[J]. Circulation,2003,108(14): 1664-1672.
[3]De Keyzer D, Karabina SA, Wei W, et al.Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol.2009 Dec;29(12):2041-6. Epub 2009 Oct 1.
[4]Winkler K, Winkelmann B R, Scharnagl H, et al. Platelet-activating factor acetylyhdrolase activity in-dicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study [J]. Circulation,2005, 111(8):980-987.
[5]Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk? Prog Cardiovasc Nurs.2009 Dec;24(4):181-9.
[6]Dohi T, Daida H. Change of concept and pathophysiology in acute coronary syndrome. Nippon Rinsho.2010 Apr;68(4):592-6.
[7]Fang CH, Li JJ, et al. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses.2005;64(1):192-6.
[8]Corestti J P, Rainwater D L, MOSS A J, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J]. Clin Chem,2006, 52(7):1331-1338.
[9]Forrester J S. Prevention of plaque rupture: a new paradigm of therapy [J]. Ann Intern Med, 2002,137(10):823-833.
[10]Packard CJ, O'Reilly DS, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group [J]. N Engl J Med,2000,343:1148-55.
[11]Koenig W, Meisinger C, Trischler G, et al. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation.2004;110:1903-8.
[12]Oei H-HS, van der Meer IM, Hofman A, et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischaemic stroke:the Rotterdam Study, Circulation,2005; 111:570-575.
[13]Bergovec M, Vrazic H, et al. Features and pathophysiology of acute coronary syndrome. Acta Med Croatica.2009 Feb;63(1):3-7.
[14]Tokumura A, Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids[J]. Biochim biophys Acta,2002, 1582:18-25.
[15]Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions[J]. Proc Natl ACHD Sci USA,1999,96:6931-6936.
[16]Lavi S, McConnell JP, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in human[J]. Circulation.2007 May 29;115(21): 2715-2721.
[17]Singh N, Tamariz J, et al. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. MiniRev Med Chem.2009 Oct;9(11):1272-83.
[18]Halcox JP, Deanfield JE. Beyond the laboratory:clinical implications for statin pleiotropy. Circulation,2004,109(21 suppll):1142-1148.
[19]Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis,2003,14(4):329-334.
[20]Rezaie-Maid A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol,2002,22(7): 1194-1199.
[21]Braun LT, Davidson MH. Lp-PLA2:A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan;12(1):29-33.
[22]Sparrow CP, Burton CA,Hermandez, et al. Simvastatin has anti-inflammatory and antiatheosclerotic activies independent of plasma cholesterol lowering. Arteroscler Thromb Vasc Biol,2001,21:115-121.
[23]Bonetti PO, Lerman LO, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003,24(3):225-248.
[24]Weitz-Schmidt G, Welzenbach K, etal. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med,2001,7:687-692.
[25]Case CC, Ballantyne CM. Statins and inflammatory markers. Curr Atheroscler Rep,2002, 4(1):42-27.
[26]Ongini E, Impagnatiello F, etal. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Nati Acad SCI USA.2004 Jun 1;101(22):8497-502.
[27]Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by marcophages. Arteroscler Thromb Vasc Biol,1998,18:1671-1678.
[28]Zeki AA, Franzi L, etal. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med.2009 Oct 15;180(8):731-40.
[29]Arnaud C, Burger F, etal. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol.2005 Jun;25(6):1231-6.
[30]Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-nethylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 1997,272:31725-29.
[31]Hernandez-perera O, Effects of the 3-hydroxy-3-nethylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin invest,1998,101:2711-19.
[32]Rikitake Y, Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol,2000,20:61-69.
[33]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA,2004,291:1071-1080.
[34]Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes The MIRCLE Study: randomized controlled. JAMA,2001,285:1711-1718.
[35]O'Donoghue M, Morrow DA. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial [J]. Circulation,2006,113(14):1745-1752.
[1]De Keyzer D, Karabina SA, Wei W, et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol.2009 Dec;29(12):2041-6.
[2]Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part Ⅰ[J]. Circulation,2003,108(14):1664-72.
[3]Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase[J]. Atheroscler,2002,3(Suppl):57-68.
[4]Winkler K, Winkelmann B R, Scharnagl H, et al. Platelet-activating factor acetylyhdrolase activity in-dicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study [J]. Circulation,2005, 111(8):980-987.
[5]Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2):a promising vascular-specific marker for screening cardiovascular risk? Prog Cardiovasc Nurs.2009 Dec;24(4):181-9.
[6]Oei H-HS, vander Meer IM, Hofman A, etal. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischaemic stroke: the Rotterdam Study, Circulation,2005; 111:570-575.
[7]Koenig W, Meisinger C, Trischler G, et al. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation.2004;110:1903-8.
[8]Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med.2000;343:1148-55.
[9]Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation.2004; 109:837-42.
[10]Iribarren C, Gross MD, Darbinian JA, et al. Relation of lipoprotein-associated phospholipase A2 mass and activity with coronary artery calcification in young adults: the CARDIA study. Arterioscl Thromb Vasc Biol.2005;25:1-7.
[11]Brilakis ES, McConnell JP, Lennon RJ, etal. Association of lipoprotein-associated phospholipase A2 levels with coronary artery discase risk factors, angio-graphic coronary artery disease, and major adverse events at follow-up. Eur Heart J,2005,26:137-144.
[12]Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis.2000; 150:413-19.
[13]Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis.2005; 182:181-8.
[14]Sudhir K.Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab.2005 May; 90(5):3100-5.
[15]Wang WY, Li J, Yang D, et al. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res.2010 Mar 1;85(4):845-52.
[16]Theilmeier G, de Geest B, van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-mice[J]. FASEB J,2000,14: 2032-2039.
[17]Tokumura A, Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids[J]. Biochim biophys Acta,2002, 1582:18-25.
[18]Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions[J]. Proc Natl ACHD Sci USA,1999,96:6931-6936.
[19]Kolodgie FD, Burke AP, Skorija KS. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol,2006,26:2523-2529.
[20]Lavi S, McConnell JP, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in human[J]. Circulation.2007 May 29;115(21): 2715-2721.
[21]Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med,1999,340:115-126.
[22]Crisby M. Modulation of the inflammatory process by statins. Drugs Today (Barc).2003, 39(2):137-143.
[23]Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation,2004, 109(21 suppl 1):110-112.
[24]Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin, 2003,21(3):315-325.
[25]黄岚 黄德嘉 动脉粥样硬化的抗炎治疗《血管损伤性疾病-从分子到临床》人民卫生出版社2008;327-333.
[26]Steffens S, Mach F. Anti-inflammatory properties of statins. Semin Vasc Med.2004 Nov;4(4):417-22.
[27]Bonetti PO, Lerman LO, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003,24(3):225-248.
[28]Weitz-Schmidt G, Welzenbach K, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med,2001,7:687-692.
[29]Case CC, Ballantyne CM. Statins and inflammatory markers. Curr Atheroscler Rep,2002, 4(1):42-27.
[30]Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by marcophages. Arteroscler Thromb Vasc Biol,1998,18:1671-1678.
[31]Egashira K, Ni W, Inoue S, et al. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res,2000,23(4):353-358.
[32]Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis,2003,14(4):329-334.
[33]Qiao Z, Ren J, Chen H. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res.2009 Jul-Aug;37(4):1029-37.
[34]Rezaie-Maid A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol,2002,22(7): 1194-1199.
[35]Sparrow CP, Burton CA,Hermandez, et al. Simvastatin has anti-inflammatory and antiatheosclerotic activies independent of plasma cholesterol lowering. Arteroscler Thromb Vasc Biol,2001,21:115-121.
[36]赵水平李向平等他汀的抗炎作用《他汀类药物治疗学》中南大学出版社2005;181-188.
[37]Braun LT, Davidson MH. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan;12(1):29-33.
[38]O'Donoghue M, Morrow DA. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial [J]. Circulation,2006,113(14):1745-1752.
[39]Ghainsom D Kom, Edzard Schwedhelm, Renke Maas, et al. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol.2007 June; 63(6):672-679.
[40]Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol.2009 Aug;20(4):327-32.
[41]Bui QT, Wilensky RL Darapladib. Expert Opin Investig Drugs.2010 Jan;19(1):161-8.
[42]Blackie JA, Bloomer JC. The identification of clinical candidate SB-480848:a potent inhibitor of lipoprotein-associated phospholipase A2 [J]. Bioorg Med Chem Lett,2003,13(6): 1067-1070.
[43]Patrick W. Serruys, MD, PhD Hector M. Garcia-Garcia. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque.Circulation.2008;118:1172-1182.
[44]Suckling KE.Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs.2009 Oct;18(10):1425-30.
[2]Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies:Part Ⅰ[J]. Circulation,2003,108(14): 1664-1672.
[3]De Keyzer D, Karabina SA, Wei W, et al.Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol.2009 Dec;29(12):2041-6. Epub 2009 Oct 1.
[4]Winkler K, Winkelmann B R, Scharnagl H, et al. Platelet-activating factor acetylyhdrolase activity in-dicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study [J]. Circulation,2005, 111(8):980-987.
[5]Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk? Prog Cardiovasc Nurs.2009 Dec;24(4):181-9.
[6]Dohi T, Daida H. Change of concept and pathophysiology in acute coronary syndrome. Nippon Rinsho.2010 Apr;68(4):592-6.
[7]Fang CH, Li JJ, et al. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses.2005;64(1):192-6.
[8]Corestti J P, Rainwater D L, MOSS A J, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J]. Clin Chem,2006, 52(7):1331-1338.
[9]Forrester J S. Prevention of plaque rupture: a new paradigm of therapy [J]. Ann Intern Med, 2002,137(10):823-833.
[10]Packard CJ, O'Reilly DS, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group [J]. N Engl J Med,2000,343:1148-55.
[11]Koenig W, Meisinger C, Trischler G, et al. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation.2004;110:1903-8.
[12]Oei H-HS, van der Meer IM, Hofman A, et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischaemic stroke:the Rotterdam Study, Circulation,2005; 111:570-575.
[13]Bergovec M, Vrazic H, et al. Features and pathophysiology of acute coronary syndrome. Acta Med Croatica.2009 Feb;63(1):3-7.
[14]Tokumura A, Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids[J]. Biochim biophys Acta,2002, 1582:18-25.
[15]Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions[J]. Proc Natl ACHD Sci USA,1999,96:6931-6936.
[16]Lavi S, McConnell JP, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in human[J]. Circulation.2007 May 29;115(21): 2715-2721.
[17]Singh N, Tamariz J, et al. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. MiniRev Med Chem.2009 Oct;9(11):1272-83.
[18]Halcox JP, Deanfield JE. Beyond the laboratory:clinical implications for statin pleiotropy. Circulation,2004,109(21 suppll):1142-1148.
[19]Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis,2003,14(4):329-334.
[20]Rezaie-Maid A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol,2002,22(7): 1194-1199.
[21]Braun LT, Davidson MH. Lp-PLA2:A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan;12(1):29-33.
[22]Sparrow CP, Burton CA,Hermandez, et al. Simvastatin has anti-inflammatory and antiatheosclerotic activies independent of plasma cholesterol lowering. Arteroscler Thromb Vasc Biol,2001,21:115-121.
[23]Bonetti PO, Lerman LO, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003,24(3):225-248.
[24]Weitz-Schmidt G, Welzenbach K, etal. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med,2001,7:687-692.
[25]Case CC, Ballantyne CM. Statins and inflammatory markers. Curr Atheroscler Rep,2002, 4(1):42-27.
[26]Ongini E, Impagnatiello F, etal. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Nati Acad SCI USA.2004 Jun 1;101(22):8497-502.
[27]Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by marcophages. Arteroscler Thromb Vasc Biol,1998,18:1671-1678.
[28]Zeki AA, Franzi L, etal. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med.2009 Oct 15;180(8):731-40.
[29]Arnaud C, Burger F, etal. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol.2005 Jun;25(6):1231-6.
[30]Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-nethylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 1997,272:31725-29.
[31]Hernandez-perera O, Effects of the 3-hydroxy-3-nethylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin invest,1998,101:2711-19.
[32]Rikitake Y, Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol,2000,20:61-69.
[33]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA,2004,291:1071-1080.
[34]Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes The MIRCLE Study: randomized controlled. JAMA,2001,285:1711-1718.
[35]O'Donoghue M, Morrow DA. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial [J]. Circulation,2006,113(14):1745-1752.
[1]De Keyzer D, Karabina SA, Wei W, et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol.2009 Dec;29(12):2041-6.
[2]Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part Ⅰ[J]. Circulation,2003,108(14):1664-72.
[3]Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase[J]. Atheroscler,2002,3(Suppl):57-68.
[4]Winkler K, Winkelmann B R, Scharnagl H, et al. Platelet-activating factor acetylyhdrolase activity in-dicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study [J]. Circulation,2005, 111(8):980-987.
[5]Lee JH, Engler MM. Lipoprotein-associated phospholipase A(2):a promising vascular-specific marker for screening cardiovascular risk? Prog Cardiovasc Nurs.2009 Dec;24(4):181-9.
[6]Oei H-HS, vander Meer IM, Hofman A, etal. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischaemic stroke: the Rotterdam Study, Circulation,2005; 111:570-575.
[7]Koenig W, Meisinger C, Trischler G, et al. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation.2004;110:1903-8.
[8]Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med.2000;343:1148-55.
[9]Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation.2004; 109:837-42.
[10]Iribarren C, Gross MD, Darbinian JA, et al. Relation of lipoprotein-associated phospholipase A2 mass and activity with coronary artery calcification in young adults: the CARDIA study. Arterioscl Thromb Vasc Biol.2005;25:1-7.
[11]Brilakis ES, McConnell JP, Lennon RJ, etal. Association of lipoprotein-associated phospholipase A2 levels with coronary artery discase risk factors, angio-graphic coronary artery disease, and major adverse events at follow-up. Eur Heart J,2005,26:137-144.
[12]Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis.2000; 150:413-19.
[13]Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis.2005; 182:181-8.
[14]Sudhir K.Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab.2005 May; 90(5):3100-5.
[15]Wang WY, Li J, Yang D, et al. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res.2010 Mar 1;85(4):845-52.
[16]Theilmeier G, de Geest B, van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-mice[J]. FASEB J,2000,14: 2032-2039.
[17]Tokumura A, Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids[J]. Biochim biophys Acta,2002, 1582:18-25.
[18]Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions[J]. Proc Natl ACHD Sci USA,1999,96:6931-6936.
[19]Kolodgie FD, Burke AP, Skorija KS. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol,2006,26:2523-2529.
[20]Lavi S, McConnell JP, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in human[J]. Circulation.2007 May 29;115(21): 2715-2721.
[21]Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med,1999,340:115-126.
[22]Crisby M. Modulation of the inflammatory process by statins. Drugs Today (Barc).2003, 39(2):137-143.
[23]Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation,2004, 109(21 suppl 1):110-112.
[24]Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin, 2003,21(3):315-325.
[25]黄岚 黄德嘉 动脉粥样硬化的抗炎治疗《血管损伤性疾病-从分子到临床》人民卫生出版社2008;327-333.
[26]Steffens S, Mach F. Anti-inflammatory properties of statins. Semin Vasc Med.2004 Nov;4(4):417-22.
[27]Bonetti PO, Lerman LO, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003,24(3):225-248.
[28]Weitz-Schmidt G, Welzenbach K, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med,2001,7:687-692.
[29]Case CC, Ballantyne CM. Statins and inflammatory markers. Curr Atheroscler Rep,2002, 4(1):42-27.
[30]Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by marcophages. Arteroscler Thromb Vasc Biol,1998,18:1671-1678.
[31]Egashira K, Ni W, Inoue S, et al. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res,2000,23(4):353-358.
[32]Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis,2003,14(4):329-334.
[33]Qiao Z, Ren J, Chen H. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res.2009 Jul-Aug;37(4):1029-37.
[34]Rezaie-Maid A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol,2002,22(7): 1194-1199.
[35]Sparrow CP, Burton CA,Hermandez, et al. Simvastatin has anti-inflammatory and antiatheosclerotic activies independent of plasma cholesterol lowering. Arteroscler Thromb Vasc Biol,2001,21:115-121.
[36]赵水平李向平等他汀的抗炎作用《他汀类药物治疗学》中南大学出版社2005;181-188.
[37]Braun LT, Davidson MH. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan;12(1):29-33.
[38]O'Donoghue M, Morrow DA. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial [J]. Circulation,2006,113(14):1745-1752.
[39]Ghainsom D Kom, Edzard Schwedhelm, Renke Maas, et al. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol.2007 June; 63(6):672-679.
[40]Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol.2009 Aug;20(4):327-32.
[41]Bui QT, Wilensky RL Darapladib. Expert Opin Investig Drugs.2010 Jan;19(1):161-8.
[42]Blackie JA, Bloomer JC. The identification of clinical candidate SB-480848:a potent inhibitor of lipoprotein-associated phospholipase A2 [J]. Bioorg Med Chem Lett,2003,13(6): 1067-1070.
[43]Patrick W. Serruys, MD, PhD Hector M. Garcia-Garcia. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque.Circulation.2008;118:1172-1182.
[44]Suckling KE.Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs.2009 Oct;18(10):1425-30.